Treatment with Crexont statistically significantly improved “On” time without troublesome dyskinesia compared with carbidopa/levodopa IR. The Food and Drug Administration (FDA) has approved Crexont ® ...
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion for Onerji (levodopa/carbidopa, Tanabe Pharma) for the treatment of adults with ...
The FDA issued a safety communication today warning of a potential increased risk of seizures tied to certain medications used to treat Parkinson's disease. The agency will require manufacturers of ...
Amneal to hold CREXONT launch symposium and scientific presentations at the International Congress of Parkinson’s Disease and Movement Disorders on Sept. 27 – Oct. 1, 2024 BRIDGEWATER, N.J.--(BUSINESS ...
Share on Pinterest Scientists have developed a weekly injectable treatment for Parkinson’s disease. Chalit Saphaphak/Stocksy Parkinson’s symptoms develop slowly, most commonly after the age of 50, and ...
Clinicians should monitor vitamin B6 levels in Parkinson disease patients taking carbidopa/levodopa due to a risk for deficiency-linked seizures. Reports of seizures linked to vitamin B6 deficiency in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results